Altimmune (ALT) Preferred Stock Liabilities (2017 - 2018)
Altimmune's (ALT) quarterly Preferred Stock Liabilities came in at $917.0 in Q3 2018, down 99.99% year-on-year from $8.2 million in Q3 2017, and down 99.51% on a QoQ basis from $186685.0 in Q2 2018.
Altimmune (ALT) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Altimmune (ALT) has 2 years of Preferred Stock Liabilities data on file, last reported at $917.0 in Q3 2018.
- On a quarterly basis, Preferred Stock Liabilities fell 99.99% year-over-year to $917.0 in Q3 2018; TTM through Sep 2018 was $917.0, a 99.99% decrease from a year earlier, with the FY2017 full-year figure at $27236.0, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2018 stood at $917.0, down from $186685.0 in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for ALT reached as high as $8.2 million in Q3 2017 and fell as low as $917.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Altimmune | 7.96 Mn | 7.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 917.00 |
| Jun 30, 2018 | 186,685.00 |
| Mar 31, 2018 | 34,278.00 |
| Dec 31, 2017 | 27,236.00 |
| Sep 30, 2017 | 8.24 Mn |